Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with relapsed ovarian cancer.
Epistemonikos ID: ff5e0141984b69f3ae7199aa2c349d297cc48cb5
First added on: May 08, 2024